No Detail Found!

In silico-based identification of phytochemicals as novel human phosphoglycerate mutase 1 (PGAM1) inhibitors for cancer therapy

Author(s)
Nazia Kanwal Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad,Faisalabad,Pakistan
Azhar Rasul Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad,Faisalabad,Pakistan
Muhammad Ajmal Shah Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Government College University,Faisalabad,Pakistan
Farhat Jabeen Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad,Faisalabad,Pakistan
Tayyaba Sultana Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad,Faisalabad,Pakistan
Abstract
Targeting cancer-specific metabolic and mitochondrial remodeling has emerged as a novel and selective strategy for cancer therapy during recent years. Phosphoglycerate Mutase 1 (PGAM1) is an important glycolytic enzyme that catalyzes the conversion of 3-phosphoglycerate to 2-phosphoglycerate and plays a critical role in cancer progression by coordinating glycolysis and biosynthesis. PGAM1 has been reported to be over expressed in a variety of cancer types and its inhibition results in decreased tumor growth and metastasis. Recently, there has been a growing interest in identification and characterization of novel PGAM1 inhibitors for the treatment of cancer. In the current study, in silico tools were used to find out natural inhibitors of PGAM1. For docking studies, a database of 5006 phytochemicals were docked against PGAM1, using MOE software in order to identify the compounds which show better binding affinities than PGMI-004A. Out of 5006 compounds screened, eight compounds (1,3-cyclopentanedione, glyflavanone B, 6demethoxytangeretin, gnaphaliin, lantalucratin A and -(-) morelensin, abyssinin II and monotesone-A) showed significant binding affinity with PGAMI active site. Further, the eight selected compounds were evaluated for different pharmacokinetics parameters using admetSAR, the obtained results demonstrated that none of these hit compounds violated Lipinski's drug rule of 5 and all the hit compounds possess favorable ADMET properties. This study has unveiled the potential of phytochemicals that could serve as probable lead candidates for the development of PGAM1 inhibitors as anti-cancer agents.
Publication Details
Page(s) 665-670
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: SUP2, Year: 2021

Request the full text from PASTIC

Keywords
PGAM1, Cancer metabolism, computational analyses, Phytochemicals, molecular operating environment
References
Arruebo M,Vilaboa N,Saez-Gutierrez B,Lambea J,Tres A,Valladares M,Gonzalez-Fernandez A .2011 .Assessment of the evolution of cancer treatment therapies. Cancers (Basel), 3(3) : 3279-3330.
Ashfaq UA,Mumtaz A,Qamar TU,Fatima T .2013 .Medicinal plant activities, phytochemical and structural database. Bioinformation, 9(19) : 993-995.
Benet LZ,Hosey CM,Ursu O,Oprea TI .2016 .BDDCS, the Rule of 5 and drugability. Adv. Drug Deliv. Rev., 101 : 89-98.
Bray F,Ferlay J,Soerjomataram I,Siegel RL,Torre LA,Jemal A,Clin A .2018 .Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Global cancer statistics, 68(6) : 394-424.
Daina A,Michielin O,Zoete V .2017 .SwissADME: a free web tool to evaluate pharmacokinetics, druglikeness and medicinal chemistry friendliness of small molecules. Sci. Rep, 7(1) : 42717.
Evans MJ,Morris GM,Wu J,Olson AJ,Sorensen EJ,Cravatt BF .2007 .Mechanistic and structural requirements for active site labeling of phosphoglycerate mutase by spiroepoxides. Mol. Biosyst, 3(7) : 495-506.
Evans MJ,Saghatelian A,Sorensen EJ,Cravatt BF .2005 .Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat. Biotechnol, 23(10) : 1303-1307.
Hayashi K,Chang FR,Nakanishi Y,Bastow KF,Cragg G,McPhail AT,Nozaki H,Lee KH H,Lantalucratins A-F .2004 .new cytotoxic naphthoquinones from Lantana involucrata. J. Nat. Prod, 67(6) : 990-993.
Hitosugi T,Zhou L,Elf S,Fan J,Kang HB,Seo JH,Shan C,Dai Q,Zhang L,Xie J,Gu TL,Jin P,Aleckovic M,LeRoy G,Kang Y,Sudderth JA,DeBerardinis RJ,Luan CH,Chen GZ,Muller S,Shin DM,Owonikoko TK,Lonial S,Arellano ML,Khoury HJ,Khuri FR,Lee BH,Ye K,Boggon TJ,Kang S,He C,Chen J .2012 .Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell, 22(5) : 585-600.
Hitosugi T,Zhou L,Fan J,Elf S,Zhang L,Xie J,Wang Y,Gu TL,Aleckovic M,LeRoy G,Kang Y,Kang HB,Seo JH,Shan C,Jin P,Gong W,Lonial S,Arellano ML,Khoury HJ,Chen GZ,Shin DM,Khuri FR,Boggon TJ,Kang S,He C,Chen J .2013 .Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. Nat. Commun, 4(1) : 1790.
Huang K,Jiang L,Liang R,Li H,Ruan X,Shan C,Ye D,Zhou L D .2019 .Synthesis and biological evaluation of anthraquinone derivatives as allosteric phosphoglycerate mutase 1 inhibitors for cancer treatment. Eur. J. Med, 168 : 45-57.
Idrees S,Ashfaq UA .2014 .Discovery and design of cyclic peptides as dengue virus inhibitors through structure-based molecular docking. Asian Pac. J. Trop. Med, 7(7) : 513-516.
Kalyanaraman B .2017 .Teaching the basics of cancer metabolism: Developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism. Redox. Biol, 12 : 833-842.
Khan M,Qasim M,Ashfaq UA,Idrees S,Shah M .2013 .Computer aided screening of Accacia nilotica phytochemicals against HCV NS3/4a. , 9(14) : 710-714.
Krishnamoorthy K and Subramaniam P .2014 .Phytochemical profiling of leaf, stem, and tuber parts of Solena amplexicaulis (Lam.) Gandhi using GC-MS. Int. Sch. Res. Notices, 567409 : .
Li X,Tang S,Wang QQ,Leung EL,Jin H,Huang Y,Liu J,Geng M,Huang M,Yuan S,Yao XJ,Ding J,Pharmacol Front .2017 .Identification of epigallocatechin-3-gallate as an inhibitor of phosphoglycerate mutase 1. , 8 : 325.
Makovec T .2019 .Cisplatin and beyond: Molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol, 53(2) : 148-158.
Muhseen ZT,Li G .2019 .Promising terpenes as natural antagonists of cancer: An in-silico approach. , 25(1) : .
Mumtaz A,Ashfaq UA,Ul Qamar MT,Anwar F,Gulzar F,Ali MA,Saari N,Pervez MT .2017 .MPD3: A useful medicinal plants database for drug designing. Nat. Prod. Res., 31(11) : 1228-1236.
Oyinloye BE,Adekiya TA,Aruleba RT,Ojo OA,Ajiboye BO .2019 .Structure-based docking studies of glut4 towards exploring selected phyto-chemicals from Solanum xanthocarpum as a therapeutic target for the treatment of cancer. Curr. Drug. Discov, 16(4) : 406-416.
Pavlova NN,Thompson CB .2016 .The emerging hallmarks of cancer metabolism. Cell Metab, 23(1) : 27-47.
Ren J,Xu YY,Jiang HF,Yang M,Huang QH,Yang J,Hu K,Wei K K .2014 .Solena amplexicaulis induces cell cycle arrest, apoptosis and inhibits angiogenesis in hepatocarcinoma cells and HUVECs. Am. J. Chin. Med, 42(6) : 1521-1537.
Sarfraz I,Rasul A,Hussain G,Hussain SM,Ahmad M,Nageen B,Jabeen F,Ali Selamoglu Z,M Selamoglu Z .2018 .Malic enzyme 2 as a potential therapeutic drug target for cancer. IUBMB Life, 70(11) : 1076-1083.
Sharif F,Rasul A,Ashraf A,Hussain G,Younis T,Sarfraz I,Chaudhry MA,Bukhari SA,Ji XY,Selamoglu Z,Ali M .2019 .Phosphoglycerate mutase 1 in cancer: A promising target for diagnosis and therapy. IUBMB Life, 71(10) : 1418-1427.
Wang P,Jiang L,Cao Y,Zhang X,Chen B,Zhang S,Huang K,Ye D,Zhou L D .2018 .Xanthone derivatives as phosphoglycerate mutase 1 inhibitors: Design, synthesis, and biological evaluation. Bioorg Med. Chem, 26(8) : 1961-1970.
0

Citations

0

Downloads

10

Views